Overview

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy

Status:
Unknown status

Trial end date:
2020-08-31

Target enrollment:

Participant gender:

Summary

The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.